adenine and bictegravir

adenine has been researched along with bictegravir in 67 studies

Research

Studies (67)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	18 (26.87)	24.3611
2020's	49 (73.13)	2.80

Authors

Authors	Studies
Benson, P; Brinson, C; Cheng, A; Crofoot, G; DeJesus, E; Dretler, R; Martin, H; Mills, A; Peloquin, J; Quirk, E; Sax, PE; Ward, D; Wei, X; White, K	1
Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D	1
Antinori, A; Cheng, A; Custodio, J; DeJesus, E; Garner, W; Koenig, E; Montes, ML; Pozniak, A; Quirk, E; Reynes, J; Sax, PE; SenGupta, D; Slim, J; Stellbrink, HJ; White, K; Workowski, K	1
Jones, J; Taylor, BS; Tieu, HV; Wilkin, TJ	1
Castagna, A; Lazzarin, A; Spagnuolo, V	1
Harris, M	1
Andreatta, K; Cheng, A; Creticos, C; Crofoot, G; Custodio, J; Daar, ES; DeJesus, E; Graham, H; Koenig, E; Liu, YP; Martin, H; Molina, JM; Oguchi, G; Quirk, E; Rockstroh, JK; Ruane, P	1
Clarke, A; Garner, W; Laouri, M; Maggiolo, F; Martin, H; Quirk, E; Wohl, D	1
Byland, E; Canupp, K; Dunlap, J; Mospan, C; Mospan, G; Whitaker, WB; Xiong, L	1
Mesplède, T; Pham, HT	1
Acosta, RK; Chang, S; Garner, W; Lutz, J; Majeed, S; Martin, H; Martin, R; Quirk, E; SenGupta, D; Wei, X; White, KL; Willkom, M	1
Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y	1
Barber, TJ	1
Acosta, R; Albrecht, H; Arribas, JR; Brainard, D; Collins, SE; Creticos, C; Maggiolo, F; Martin, H; Martorell, CT; Sax, PE; Stellbrink, HJ; Stephens, JL; Wei, X	1
Andreatta, K; Chang, S; Graham, H; Liu, H; Liu, YP; Martin, H; Martin, R; Quirk, E; Wei, L; White, KL; Willkom, M	1
Acosta, RK; Avihingsanon, A; Cao, H; Chetchotisakd, P; DeJesus, E; Gankina, N; Hagins, D; Kityo, C; Koenig, E; Makadzange, T; Martin, H; Pokrovsky, V; Quirk, E; Stephens, JL; Supparatpinyo, K; Voronin, E; Wang, H	1
Bhatia, R; Rizza, S; Temesgen, Z; Zeuli, J	1
Di Perri, G	1
Álvarez, M; Chueca, N; Collado, A; de Salazar, A; Fernández, JM; Fernández-Fuertes, E; García, F; Lozano, AB	1
Badowski, ME; Biagi, MJ; Chiampas, TD; Michienzi, SM; Patel, MC; Schriever, CA; Young, JD	1
Adam, A; Buhk, T; Fenske, S; Hansen, S; Hoffmann, C; Sabranski, M; Schewe, K; Stellbrink, HJ	1
André-Garnier, E; Charpentier, C; Ferré, V; Hingrat, QL; Leducq, V; Malet, I; Marcelin, AG; Peytavin, G; Raffi, F; Reliquet, V; Rodallec, A	1
Hill, A; Venter, WDF	1
Bremner, S; Bruce, C; Churchill, D; Geretti, AM; Iwuji, CC; Lambert, D; Orkin, C; Perry, N; To, Y; Waters, L	1
Acosta, RK; Andreatta, K; Collins, S; Liu, H; Martin, H; Martin, R; Parvangada, A; White, KL; Willkom, M	1
Alonso-Vega, GG; Ferrández, JS; García, AL; García, TM; González, AO	1
Babusis, D; Barouch, DH; Bekerman, E; Callebaut, C; Campigotto, F; Cihlar, T; Cox, S; Das, M	1
Alrubayyi, A; Burns, F; Fisher-Pearson, N; Gilson, R; Griffith, SA; Gupta, RK; Kinloch, S; McCoy, LE; Muir, L; Pellegrino, P; Peppa, D; Rees-Spear, C; Rowland-Jones, S; Touizer, E; Waters, L	1
Bamoulid, J; Clairet, AL; Davani, S; Ducloux, D; Flammang, M; Lagoutte-Renosi, J; Lepiller, Q; Muret, P; Royer, PY	1
Andreatta, K; Berger, D; Blair, C; Brainard, DM; Brar, I; Collins, SE; Hagins, D; Hileman, CO; Kumar, P; Martin, H; McDonald, C; Osiyemi, O; Ramgopal, MN; Saag, M; Wurapa, AK	1
Ajana, F; Brainard, D; Chuck, SK; Collins, SE; Gandhi-Patel, B; Kityo, C; Koenig, E; Liu, Y; Makadzange, T; McNicholl, I; Natukunda, E; Orkin, C; Pikora, C; Wang, H; Wei, X; White, K	1
Barrail-Tran, A; Becker, PH; Castro Gordon, A; Catalan, P; Chéret, A; Furlan, V; Gasnault, J; Gelé, T; Gouget, H; Goujard, C; Nkam, L; Pallier, C; Taburet, AM	1
Bazzi, R; Roa, PE	1
Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY	1
Gelman, M; Holmes, J; Kraft, J; Mayer, KH; Melbourne, K; Mimiaga, MJ	1
Acosta, R; Andreatta, K; Blair, C; Chang, S; Collins, SE; D'Antoni, ML; Daar, ES; Gallant, J; Hagins, D; Liu, H; Martin, H; Martin, R; McNicholl, I; Molina, JM; Sax, PE; White, KL	1
Bookstaver, PB; Clary, JC; Derrick, C; Drummond, M; Rowe, SM; Sanasi, K	1
Berenguer, J; Blair, C; Chuck, SK; D'Antoni, ML; De Wit, S; Gallant, J; Haubrich, R; Maggiolo, F; Martin, H; McNicholl, IR; Molina, JM; Piontkowsky, D; Pulido, F; Rizzardini, G; Vandekerckhove, L	1
Bernardino, JI; de Gea Grela, A; Martín Carbonero, L; Micán, R; Ramos, L; Valencia, ME	1
Chang, HY; Chang, SF; Chang, SY; Chen, GJ; Chen, LY; Chuang, YC; Hsieh, SM; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Sheng, WH; Su, YC; Sun, HY; Wu, PY	1
Andreoni, M; Antinori, A; Armenia, D; Berno, G; Bertoli, A; Borghi, V; Buonomini, A; Ceccherini-Silberstein, F; Cicalini, S; Forbici, F; Gagliardini, R; Gennari, W; Lanini, S; Latini, A; Malagnino, V; Mussini, C; Perno, CF; Santoro, MM; Sarmati, L; Teti, E	1
Arribas, JR; Bernardino, JI; Busca, C; Cadiñanos, J; de Gea Grela, A; de Miguel, R; González-García, J; Martín-Carbonero, L; Micán, R; Montejano, R; Montes, ML; Moreno, V; Pérez Valero, I; Serrano, L; Valencia, E	1
Derkach, EV; Pyadushkina, EA	1
Buscemi, L; Mossholder, B	1
Alix, A; Bois, J; Brucato, S; Dargere, S; Fournel, F; Fournier, A; Got, L; Gregoire, N; Hocqueloux, L; Lefeuvre, S; McNicholl, I; Parienti, JJ; Peyro-Saint-Paul, L; Prazuck, T; Valentin, C	1
Boodhram, R; Dooley, KE; Dorse, G; Naidoo, A; Naidoo, K; Osuala, EC; Padayatchi, N; Perumal, R; Yende-Zuma, N	1
Ondrush, NM; Sidman, EF	1
Chen, CP; Hung, CC; Hung, TC; Lee, CH; Lee, CY; Lee, YT; Li, CW; Liou, BH; Liu, CE; Sun, HY; Tang, HJ; Tsai, MS; Yang, CJ	1
Alcalá, JC; Castro, A; Grau, S; Miró, JM; Olalla, J; Rubio-Rodríguez, D; Rubio-Terrés, C	1
Eckardt, PA; Montalvo, S; Partosh, D; Sherman, EM; Unger, N	1
Baldi, A; Carleo, MA; Contieri, M; De Blasiis, P; De Luca, A; Esposito, V; Guerra, G; Guida, A; Hay, E; Lucariello, A; Maggi, P; Mascolo, S; Perna, A; Sellitto, C	1
Baeten, JM; Benson, P; Berhe, M; Crofoot, G; Dvory-Sobol, H; Gupta, SK; Koenig, E; Liu, SY; McDonald, C; Ramgopal, M; Rhee, MS; Ruane, P; Sanchez, WE; Scribner, A; Sims, J; VanderVeen, LA	1
Assoumou, L; Bachelard, A; Benalycherif, A; Charpentier, C; Descamps, D; Donadille, C; Duvivier, C; El Mouhebb, M; Ghosn, J; Isernia, V; Lacombe, K; Landman, R; Mora, M; Peytavin, G; Spire, B	1
Chang, HY; Chen, LY; Chuang, YC; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Liu, WD; Luo, YZ; Su, YC; Sun, HY; Wu, PY	1
Avihingsanon, A; Chetchotisakd, P; Kiertiburanakul, S; Martin, H; Ratanasuwan, W; Siripassorn, K; Supparatpinyo, K; Wang, H; Wang, HY; Wong, T	1
Hideta, K; Higasa, S; Hikasa, S; Kimura, T; Sawada, A; Shimabukuro, S; Tanaka, K; Tokugawa, T; Yanai, M	1
Allard, SD; Ausselet, N; Darcis, G; De Wit, S; Delforge, M; Demeester, R; Florence, E; Henrard, S; Messiaen, P; Nasreddine, R; Van Praet, J; Vandekerckhove, L; Yombi, JC	1
Guevara-Maldonado, MF; Kammar-García, A; Mancilla-Galindo, J; Mata-Marín, JA; Ortiz-Hernández, A; Pérez-Barragán, E; Pérez-Cavazos, S	1
Brumme, CJ; DeKoven, S; Naccarato, M; Tan, DHS	1
Álvarez-Díaz, AM; Esteban-Cartelle, B; Gramage-Caro, T; Montero-Llorente, B; Parro-Martín, MLÁ; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M	1
Abalat-Torrres, A; Arrieta-Aldea, I; Cañas-Ruano, E; Canepa, C; González-Mena, A; Guelar, A; Güerri-Fernández, R; Knobel, H; Knobel, P; Marcos, A; Villar-García, J	1
Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F	1
Alessio, G; Baratti, S; Basso, M; Battagin, G; Colombo, F; Giovagnorio, F; Malagnino, V; Maurici, M; Nicolè, S; Parisi, SG; Pirola, N; Rossi, MC; Sarmati, L; Storato, S; Vinci, A	1
Ardila, F; Bernal, E; Casadellà, M; Curran, A; Echeverria, P; Estrada, V; Fanciulli, C; Gutierrez, A; Hernández, C; Hidalgo-Tenorio, C; Imaz, A; Knobel, H; Lagarde, M; Lopez-Lirola, A; Macias, J; Masiá, M; Montero-Alonso, M; Morano, L; Navarro-Alcaraz, A; Parera, M; Podzamczer, D; Portilla, J; Prieto, P; Rigo, R; Rivero, A; Troya, J; Valencia, E; Vivancos, MJ	1
Espinosa, A; Horta, AM; Lázaro, A; Mendoza, I; Sánchez, L; Torralba, M	1
De Clercq, E; Huang, J; Li, G; Zhang, M; Zhang, Z	1
Ambrosioni, J; Berrocal, L; Blanch, J; Blanco, JL; Borjabad, B; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Llobet, R; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Miro, JM; Rocabert, A; Rodriguez, A; Sempere, A; Solbes, E; Torres, B	1

Reviews

9 review(s) available for adenine and bictegravir

Article	Year
Bictegravir. Current opinion in HIV and AIDS, 2018, Volume: 13, Issue:4 Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Tenofovir	2018
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:4 Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Drug Combinations; Drug Interactions; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Tablets; Tenofovir	2019
Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:11 Topics: Adenine; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; Humans; Piperazines; Pyridones; Tenofovir	2019
Clinical pharmacology of the single tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). Le infezioni in medicina, 2019, Dec-01, Volume: 27, Issue:4 Topics: Adenine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Piperazines; Pyridones; Tablets; Tenofovir	2019
Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2022, 08-05, Volume: 79, Issue:16 Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Viral Load	2022
Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023, 02-15, Volume: 80, Issue:4 Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Pyridones	2023
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature. Expert review of anti-infective therapy, 2023, Volume: 21, Issue:1 Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans	2023
Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials. HIV medicine, 2023, Volume: 24, Issue:3 Topics: Adenine; Adult; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Randomized Controlled Trials as Topic; RNA	2023
Biktarvy for the treatment of HIV infection: Progress and prospects. Biochemical pharmacology, 2023, Volume: 217 Topics: Adenine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Pyridones; Tenofovir	2023

Trials

19 trial(s) available for adenine and bictegravir

Article	Year
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. The lancet. HIV, 2017, Volume: 4, Issue:4 Topics: Adenine; Adolescent; Adult; Alanine; Amides; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load; Young Adult	2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet (London, England), 2017, Nov-04, Volume: 390, Issue:10107 Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult	2017
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori Lancet (London, England), 2017, Nov-04, Volume: 390, Issue:10107 Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult	2017
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph The lancet. HIV, 2018, Volume: 5, Issue:7 Topics: Adenine; Adult; Aged; Alanine; Amides; Anti-Retroviral Agents; Drug Substitution; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Protease Inhibitors; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult	2018
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, The patient, 2018, Volume: 11, Issue:5 Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Cohort Studies; Emtricitabine; Europe; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; United States; Young Adult	2018
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The lancet. HIV, 2019, Volume: 6, Issue:6 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load	2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-infer The lancet. HIV, 2019, Volume: 6, Issue:6 Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome	2019
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. The Journal of antimicrobial chemotherapy, 2019, 12-01, Volume: 74, Issue:12 Topics: Adenine; Adult; Alanine; Amides; Amino Acid Substitution; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; RNA, Viral; Sustained Virologic Response; Tenofovir	2019
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. Journal of acquired immune deficiency syndromes (1999), 2019, 11-01, Volume: 82, Issue:3 Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; CD4 Lymphocyte Count; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult	2019
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults BMC infectious diseases, 2020, Jul-20, Volume: 20, Issue:1 Topics: Adenine; Adult; Alanine; Amides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Pilot Projects; Piperazines; Prospective Studies; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome	2020
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. Journal of acquired immune deficiency syndromes (1999), 2020, 11-01, Volume: 85, Issue:3 Topics: Adenine; Amides; Anti-HIV Agents; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Logistic Models; Multivariate Analysis; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir	2020
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. Journal of acquired immune deficiency syndromes (1999), 2021, 09-01, Volume: 88, Issue:1 Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Black or African American; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; RNA; Tenofovir; United States; Viral Load	2021
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. Journal of acquired immune deficiency syndromes (1999), 2021, 12-01, Volume: 88, Issue:4 Topics: Adenine; Adolescent; Adult; Aged; Alanine; Amides; Anti-HIV Agents; Child; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Middle Aged; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Young Adult	2021
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age. HIV medicine, 2023, Volume: 24, Issue:1 Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir	2023
Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study. The Journal of antimicrobial chemotherapy, 2022, 12-23, Volume: 78, Issue:1 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Biological Availability; Cross-Over Studies; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir	2022
INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection i BMJ open, 2022, 11-10, Volume: 12, Issue:11 Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Pyridones; Rifampin; Tuberculosis	2022
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. The lancet. HIV, 2023, Volume: 10, Issue:1 Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; RNA; Tenofovir; Treatment Outcome; Viral Load	2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random The lancet. HIV, 2023, Volume: 10, Issue:9 Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infant, Newborn; Injection Site Reaction; Male; Middle Aged; Rilpivirine; RNA; Tenofovir; Viral Load; Young Adult	2023
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens. The Journal of antimicrobial chemotherapy, 2023, 11-06, Volume: 78, Issue:11 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Tandem Mass Spectrometry	2023

Other Studies

39 other study(ies) available for adenine and bictegravir

Article	Year
CROI 2018: Advances in Antiretroviral Therapy. Topics in antiviral medicine, 2018, Volume: 26, Issue:1 Topics: Adenine; Amides; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Congresses as Topic; Deoxyadenosines; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Tenofovir; Viral Load	2018
What did we learn from the bictegravir switch studies? The lancet. HIV, 2018, Volume: 5, Issue:7 Topics: Adenine; Adult; Alanine; Amides; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Protease Inhibitors; Pyridones; Tenofovir	2018
Drug updates and approvals: 2018 in review. The Nurse practitioner, 2018, Volume: 43, Issue:12 Topics: Adenine; Alanine; Amides; Aminophenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzodioxoles; Clonidine; Doxylamine; Drug Approval; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Indoles; Piperazines; Pyridones; Pyridoxine; Quinolones; Tenofovir; United States; United States Food and Drug Administration	2018
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:5 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir	2019
Bictegravir and dolutegravir: head to head at 96 weeks. The lancet. HIV, 2019, Volume: 6, Issue:6 Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir	2019
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient. Antiviral research, 2020, Volume: 179 Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Mutation; Piperazines; Pyridones; Tenofovir; Toxoplasmosis, Cerebral; Treatment Failure	2020
Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide. International journal of STD & AIDS, 2020, Volume: 31, Issue:4 Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinations; Emtricitabine; Gynecomastia; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Piperazines; Pyridones; Tenofovir; Treatment Outcome	2020
Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice. Antiviral therapy, 2020, Volume: 25, Issue:2 Topics: Adenine; Adult; Aged; Aged, 80 and over; Amides; Anti-HIV Agents; Depression; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Time Factors; Young Adult	2020
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure. International journal of antimicrobial agents, 2020, Volume: 56, Issue:2 Topics: Adenine; Aged; Alanine; Amides; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HEK293 Cells; HeLa Cells; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Male; Mutation; Piperazines; Pyridones; Tenofovir; Treatment Failure	2020
Weighing considerations with newer antiretrovirals. The lancet. HIV, 2020, Volume: 7, Issue:6 Topics: Adenine; Alanine; Amides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Tenofovir	2020
Successful Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment in a HIV Patient With Swallowing Difficulties. The Annals of pharmacotherapy, 2021, Volume: 55, Issue:4 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Deglutition; Drug Combinations; Emtricitabine; Female; Fruit and Vegetable Juices; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Piperazines; Pyridones; Solubility; Tenofovir	2021
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection. The Journal of antimicrobial chemotherapy, 2021, 02-11, Volume: 76, Issue:3 Topics: Adenine; Alanine; Amides; Animals; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Macaca; Male; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sexual and Gender Minorities; Tenofovir	2021
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV. The lancet. HIV, 2021, Volume: 8, Issue:6 Topics: Adenine; Adult; Alanine; Amides; Antiretroviral Therapy, Highly Active; BNT162 Vaccine; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Neutralization Tests; Piperazines; Pyridones; RNA, Viral; SARS-CoV-2; Tenofovir; Treatment Failure	2021
Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants. Journal of chemotherapy (Florence, Italy), 2022, Volume: 34, Issue:3 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Piperazines; Protease Inhibitors; Pyridones; Tacrolimus; Tenofovir	2022
Cerebrospinal fluid exposure to bictegravir/emtricitabine/tenofovir in HIV-1-infected patients with CNS impairment. The Journal of antimicrobial chemotherapy, 2021, 11-12, Volume: 76, Issue:12 Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Chromatography, Liquid; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Middle Aged; Oxazines; Piperazines; Pyridones; Tandem Mass Spectrometry; Tenofovir	2021
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer. International journal of STD & AIDS, 2022, Volume: 33, Issue:1 Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Oxazines; Pancreatic Neoplasms; Piperazines; Pyridones; Tenofovir; Treatment Outcome	2022
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. Journal of the International AIDS Society, 2021, Volume: 24, Issue:11 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Piperazines; Pyridones; Rifampin; Tenofovir	2021
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure. Journal of acquired immune deficiency syndromes (1999), 2022, 05-01, Volume: 90, Issue:1 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Piperazines; Post-Exposure Prophylaxis; Pyridones; Tenofovir	2022
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I. AIDS (London, England), 2022, 09-01, Volume: 36, Issue:11 Topics: Adenine; Adult; Alanine; Amides; Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; RNA; Tenofovir	2022
[Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2022, Volume: 35, Issue:4 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Tenofovir	2022
Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens. International journal of antimicrobial agents, 2022, Volume: 60, Issue:3 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load; Viremia	2022
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice. Journal of global antimicrobial resistance, 2022, Volume: 30 Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Piperazines; Pyridones; Tenofovir	2022
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients. AIDS (London, England), 2022, 11-15, Volume: 36, Issue:14 Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; RNA; Tenofovir	2022
[The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation]. Terapevticheskii arkhiv, 2021, Dec-15, Volume: 93, Issue:12 Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Essential; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Rilpivirine; Tenofovir	2021
Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023, 04-19, Volume: 80, Issue:9 Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Kidney Failure, Chronic; Pyridones; Quality of Life; Renal Dialysis	2023
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023, Volume: 126 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Mutation; Retrospective Studies; Tenofovir; Viral Load	2023
Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report. International journal of STD & AIDS, 2023, Volume: 34, Issue:2 Topics: Adenine; Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Kidney Failure, Chronic; Peritoneal Dialysis	2023
Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model. AIDS (London, England), 2023, 03-15, Volume: 37, Issue:4 Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Anti-HIV Agents; Cell Differentiation; HIV Infections; Humans; Integrases; Mice; Raltegravir Potassium; Tenofovir	2023
Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055. The Journal of antimicrobial chemotherapy, 2023, 03-02, Volume: 78, Issue:3 Topics: Adenine; Alanine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Prospective Studies; Pyridones	2023
Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2023, Volume: 56, Issue:3 Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Patient Reported Outcome Measures; Quality of Life; Tenofovir; Treatment Outcome	2023
Changes in Leptin to Adiponectin Ratio After Antiretroviral Therapy: A Pilot Observational Study. Current HIV research, 2023, Volume: 21, Issue:3 Topics: Adenine; Adipokines; Adiponectin; HIV Infections; Humans; Leptin; Prospective Studies	2023
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium. HIV medicine, 2023, Volume: 24, Issue:8 Topics: Adenine; Adult; Anti-HIV Agents; Belgium; Cohort Studies; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Middle Aged; Retrospective Studies; Treatment Outcome	2023
Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients. AIDS research and human retroviruses, 2023, Volume: 39, Issue:10 Topics: Adenine; Anti-HIV Agents; Cholesterol; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Weight Gain	2023
Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series. HIV medicine, 2023, Volume: 24, Issue:11 Topics: Adenine; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Tenofovir	2023
[Sleep disorders related to HIV treatment.] Revista espanola de salud publica, 2023, Jun-19, Volume: 97 Topics: Adenine; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Pyridones; Sleep Wake Disorders; Spain; Tenofovir	2023
Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study. HIV research & clinical practice, 2023, 07-20, Volume: 24, Issue:1 Topics: Adenine; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Retrospective Studies; Treatment Outcome	2023
Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study. Viruses, 2023, 08-12, Volume: 15, Issue:8 Topics: Adenine; Emtricitabine; Follow-Up Studies; Heterocyclic Compounds, 4 or More Rings; HIV Seropositivity; HIV-1; Humans; Viremia	2023
Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults. PloS one, 2023, Volume: 18, Issue:9 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones	2023
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting. The Journal of antimicrobial chemotherapy, 2023, Dec-01, Volume: 78, Issue:12 Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones; Tenofovir	2023